Parkinson’s Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis

The definition of Parkinson’s disease (PD) is changing with the expansion of clinical phenomenology and improved understanding of environmental and genetic influences that impact on the pathogenesis of the disease at the cellular and molecular level. This had led to debate and discussion with as yet, no general acceptance of the direction that change should take either at the level of diagnosis or of what should and should not be sheltered under an umbrella of PD. This article is one contribution to this on-going discussion. There are two different themes running through the article - widening the definition of PD/LBD/synucleinopathies and the heterogeneity that exists within PD itself from a clinical, pathological and genetic per-spective. The conclusion reached is that in the future, further diagnostic categories will need to be recognized. These are likely to include - Parkinson’s syndrome, Parkinson’s syndrome likely to be Lewy body PD, clinical PD (defined by QSBB criteria), Lewy body disease (PD, LBD, REM SBD) and synucleinopathies (including LBD, MSA).

[1]  J. Parkinson An Essay on the Shaking Palsy , 2002 .

[2]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[3]  Niall Quinn,et al.  Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.

[4]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[5]  C. Marsden,et al.  'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. , 1988, Brain : a journal of neurology.

[6]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[7]  Peter L. Lantos,et al.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) , 1989, Journal of the Neurological Sciences.

[8]  C. Marsden,et al.  Fronto-striatal cognitive deficits at different stages of Parkinson's disease. , 1992, Brain : a journal of neurology.

[9]  Nir Giladi,et al.  Occurrence of Parkinson's syndrome in type I Gaucher disease. , 1996, QJM : monthly journal of the Association of Physicians.

[10]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[11]  Roger Kurlan,et al.  A survey of antidepressant drug use in Parkinson's disease , 1997, Neurology.

[12]  A. Arnsten,et al.  Catecholamine regulation of the prefrontal cortex , 1997, Journal of psychopharmacology.

[13]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[14]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[15]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[16]  J Q Trojanowski,et al.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.

[17]  S. Tsuji,et al.  Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. , 1998, Neuroscience letters.

[18]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Hitoshi Takahashi,et al.  α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.

[20]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[21]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[22]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[23]  R A Crowther,et al.  Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.

[24]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[26]  G. Schellenberg,et al.  Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.

[27]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[28]  Karl J. Friston,et al.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.

[29]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[30]  E. Tolosa,et al.  Significant association between the tau gene A0/A0 genotype and Parkinson's disease , 2000, Annals of neurology.

[31]  M. Goedert,et al.  The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy , 2000 .

[32]  M. Farrer,et al.  Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p , 2000, Acta Neuropathologica.

[33]  B. Ghetti,et al.  Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 , 2011 .

[34]  L. Mucke,et al.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  V Kaasinen,et al.  Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. , 2001, Brain : a journal of neurology.

[37]  T. Robbins,et al.  Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. , 2001, Cerebral cortex.

[38]  G. Dell''Agnello,et al.  SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study , 2001, Clinical neuropharmacology.

[39]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[40]  D. Dickson,et al.  Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo. , 2002, Neurology.

[41]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[42]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[43]  N. Bohnen,et al.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. , 2003, Archives of neurology.

[44]  Andre Parent,et al.  Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.

[45]  D. D. Di Monte The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.

[46]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[47]  T. Robbins,et al.  The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. , 2004, Brain : a journal of neurology.

[48]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[49]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[50]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[51]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[52]  T. Robbins,et al.  Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism , 2004, Movement disorders : official journal of the Movement Disorder Society.

[53]  Günther Deuschl,et al.  Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.

[54]  D W Dickson,et al.  Autosomal dominant parkinsonism associated with variable synuclein and tau pathology , 2004, Neurology.

[55]  C. Marsden,et al.  l-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction , 2005, Psychopharmacology.

[56]  D. Aarsland,et al.  A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[57]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[58]  R. Kardon,et al.  Frontotemporal dementia and parkinsonism linked to chromosome 17. , 2011, Folia neuropathologica.

[59]  T. Robbins,et al.  Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[60]  M. Farrer,et al.  Parkinsonism, Lrrk2 G2019S, and tau neuropathology , 2006, Neurology.

[61]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[62]  I. McKeith,et al.  Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[63]  U. Mosimann,et al.  Orthostatic hypotension in Parkinson's disease: association with cognitive decline? , 2006, International journal of geriatric psychiatry.

[64]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[65]  Anette Schrag,et al.  Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism , 2006, The Lancet Neurology.

[66]  D. Aarsland,et al.  Changes in motor subtype and risk for incident dementia in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[67]  M. Ban,et al.  Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. , 2007, Annals of neurology.

[68]  T. Robbins Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications , 2007, Philosophical Transactions of the Royal Society B: Biological Sciences.

[69]  G. Demakis The neuropsychology of Parkinson's disease. , 2007, Disease-a-month : DM.

[70]  D. Brooks Imaging Non-Dopaminergic Function in Parkinson’s Disease , 2007, Molecular Imaging and Biology.

[71]  T. Robbins,et al.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. , 2007, Brain : a journal of neurology.

[72]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[73]  A. Siderowf,et al.  Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment , 2008, Annals of neurology.

[74]  N. Hattori,et al.  CLINICOPATHOLOGIC STUDY OF A SNCA GENE DUPLICATION PATIENT WITH PARKINSON DISEASE AND DEMENTIA , 2008, Neurology.

[75]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[76]  D. Dickson,et al.  Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson’s disease , 2008, Acta Neuropathologica.

[77]  L. Defebvre,et al.  Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[78]  D. Aarsland,et al.  A systematic review of prevalence studies of depression in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[79]  P. Mcgeer,et al.  Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[80]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[81]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[82]  V. Haroutunian,et al.  The neuropathological basis for depression in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[83]  Y Ben-Shlomo,et al.  The effect of onset age on the clinical features of Parkinson’s disease , 2009, European journal of neurology.

[84]  A. Singleton,et al.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.

[85]  T Revesz,et al.  A clinico-pathological study of subtypes in Parkinson's disease. , 2009, Brain : a journal of neurology.

[86]  Nicholas W. Wood,et al.  Genetic Variants of the α-Synuclein Gene SNCA Are Associated with Multiple System Atrophy , 2009, PloS one.

[87]  Sonja W. Scholz,et al.  SNCA variants are associated with increased risk for multiple system atrophy , 2009, Annals of neurology.

[88]  Thomas Foltynie,et al.  The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. , 2009, Brain : a journal of neurology.

[89]  A. Strafella,et al.  Impulsive and compulsive behaviors in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[90]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[91]  J. Hardy,et al.  Genetic Analysis of Pathways to Parkinson Disease , 2010, Neuron.

[92]  R. Youle,et al.  Mechanisms of mitophagy , 2010, Nature Reviews Molecular Cell Biology.

[93]  A. Goris,et al.  Association of the human leucocyte antigen region with susceptibility to Parkinson's disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[94]  Markus Tolnay,et al.  The propagation of prion-like protein inclusions in neurodegenerative diseases , 2010, Trends in Neurosciences.

[95]  J. Nutt,et al.  Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.

[96]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[97]  G. Lewis,et al.  Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials , 2010, BMC neurology.

[98]  Angie A. Kehagia,et al.  Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease , 2010, The Lancet Neurology.

[99]  Y. Ben-Shlomo,et al.  The motor phenotype of Parkinson's disease in relation to age at onset , 2011, Movement disorders : official journal of the Movement Disorder Society.

[100]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[101]  M. Farrer,et al.  MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy , 2011, Neurology.

[102]  E. Waxman,et al.  E46K Human α-Synuclein Transgenic Mice Develop Lewy-like and Tau Pathology Associated with Age-dependent, Detrimental Motor Impairment* , 2011, The Journal of Biological Chemistry.

[103]  W. Westbroek,et al.  Exploring the link between glucocerebrosidase mutations and parkinsonism. , 2011, Trends in molecular medicine.

[104]  Constantinos Kallis,et al.  Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? , 2011, Brain : a journal of neurology.

[105]  J. Stockman Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .

[106]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[107]  D. Burn,et al.  Parkinson's disease: The quintessential neuropsychiatric disorder , 2011, Movement disorders : official journal of the Movement Disorder Society.

[108]  John L. Robinson,et al.  Neuropathologic substrates of Parkinson disease dementia , 2012, Annals of neurology.

[109]  J. Holton,et al.  The neuropathology, pathophysiology and genetics of multiple system atrophy , 2012, Neuropathology and applied neurobiology.

[110]  A. Siderowf,et al.  Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[111]  M. Schwarzbold,et al.  Anxiety in Parkinson’s disease: A critical review of experimental and clinical studies , 2012, Neuropharmacology.

[112]  John Hardy,et al.  The spread of neurodegenerative disease. , 2012, The New England journal of medicine.

[113]  Harry LeVine,et al.  Corruption and Spread of Pathogenic Proteins in Neurodegenerative Diseases* , 2012, The Journal of Biological Chemistry.

[114]  J. Hardy,et al.  Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.

[115]  S. Sawcer,et al.  Systematic Review and UK‐Based Study of PARK2 (parkin), PINK1, PARK7 (DJ‐1) and LRRK2 in early‐onset Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[116]  Roger A. Barker,et al.  Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis , 2012, Neurodegenerative Diseases.

[117]  Miratul M. K. Muqit,et al.  PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65 , 2012, Open Biology.

[118]  D. Dickson Parkinson's disease and parkinsonism: neuropathology. , 2012, Cold Spring Harbor perspectives in medicine.

[119]  C. Christine,et al.  A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease , 2012, Neurology.

[120]  O. Levy,et al.  The neuropathology of genetic Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[121]  J. Trojanowski,et al.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.

[122]  M. Ban,et al.  Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. , 2013, Brain : a journal of neurology.

[123]  Christos Proukakis,et al.  A novel α-synuclein missense mutation in Parkinson disease , 2013, Neurology.

[124]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[125]  J. Hardy,et al.  α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? , 2013, Acta Neuropathologica.

[126]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.